Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 651.616K |
Day Range | - - - |
52 Wk Range | 9.600 - 45.310 |
Market Cap | $2.152B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 44 |
Short Interest | 16.62% |
Days to Cover | 12.98 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), MoonLake (NASDAQ:MLTX), Fusion Pharmaceuticals (NASDAQ:FUSN), TG Therapeutics (NASDAQ:TGTX) and PTC Therapeutics (NASDAQ:PTCT).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Oppenheimer on Monday, April 22, 2024. The analyst firm set a price target for 53.00 expecting KYMR to rise to within 12 months (a possible 50.53% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $35.21 last updated April 24, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Kymera Therapeutics.
Kymera Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.